Patients with PWS who were on GH therapy at the time of the study exhibited slightly higher sUA levels compared to GH non-users (5.7 ± 1.4 vs. 5.1 ± 1.2 mg/dL, p = 0.08) likely due to differences in FFM (47.2 ± 7.5 vs. 37.8 ± 6.8 kg, p < 0.00001). Here, GH1 is linked to Prader-Willi syndrome.